REGENXBIO receives Fast Track designation for RGX-111 gene therapy for the treatment of MPS I [Seeking Alpha]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Seeking Alpha
REGENXBIO receives Fast Track designation for RGX-111 gene therapy for the treatment of MPS IFDAgrants Fast Track designation for REGENXBIO's (NASDAQ:RGNX) RGX-111. RGX-111 is a novel, one-time investigational treatment for Mucopolysaccharidosis Type I ((MPS I)), that is designed to deliver the human iduronidase gene directly to the central nervous system using the NAV AAV9 vector.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.Click to subscribe to real-time analytics on RGNXNow read:Protalix BioTherapeutics: What The Latest Data For OPRX-106 Foretells »
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures [Yahoo! Finance]Yahoo! Finance
- REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $40.00 price target on the stock.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- REGENXBIO Sees Positive Results For Macular Degeneration Therapy [Yahoo! Finance]Yahoo! Finance
RGNX
Earnings
- 2/27/24 - Miss
RGNX
Sec Filings
- 4/17/24 - Form 4
- 4/4/24 - Form ARS
- 4/4/24 - Form DEFA14A
- RGNX's page on the SEC website